Skip to Content

Keros Therapeutics Inc KROS

Morningstar Rating
$64.95 +0.37 (0.57%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

KROS is trading at a 35% discount.
Price
$66.14
Fair Value
$344.86
Uncertainty
Extreme
1-Star Price
$656.89
5-Star Price
$83.86
Economic Moat
Psw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KROS is a good fit for your portfolio.

Trading Information

Previous Close Price
$64.58
Day Range
$63.6064.95
52-Week Range
$27.0372.39
Bid/Ask
$64.75 / $65.23
Market Cap
$2.33 Bil
Volume/Avg
26,340 / 426,200

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
136

Comparables

Valuation

Metric
KROS
CBAY
RYTM
Price/Earnings (Normalized)
Price/Book Value
6.2012.6514.63
Price/Sales
111.0131.13
Price/Cash Flow
Price/Earnings
KROS
CBAY
RYTM

Financial Strength

Metric
KROS
CBAY
RYTM
Quick Ratio
13.6310.705.27
Current Ratio
14.2510.965.58
Interest Coverage
−5.27−13.26
Quick Ratio
KROS
CBAY
RYTM

Profitability

Metric
KROS
CBAY
RYTM
Return on Assets (Normalized)
−35.62%−30.06%−46.12%
Return on Equity (Normalized)
−39.15%−51.97%−76.97%
Return on Invested Capital (Normalized)
−41.95%−30.87%−76.40%
Return on Assets
KROS
CBAY
RYTM
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFjvvvjpnChgf$571.0 Bil
VRTX
Vertex Pharmaceuticals IncNjpmtmnVzbvbvy$107.8 Bil
REGN
Regeneron Pharmaceuticals IncBvyypxxwChzhxw$106.1 Bil
MRNA
Moderna IncQvqkznmgVlv$42.3 Bil
ARGX
argenx SE ADRQfmbxrxvBrgj$23.7 Bil
BNTX
BioNTech SE ADRDvgdplglBzdrw$22.1 Bil
ALNY
Alnylam Pharmaceuticals IncDfqgjzhztFdybfdz$19.4 Bil
BMRN
Biomarin Pharmaceutical IncBvfsznlxVkkbks$16.7 Bil
RPRX
Royalty Pharma PLC Class ASjnwzpfgrtRjmdfs$13.6 Bil
INCY
Incyte CorpFrpqtfxRkzhp$12.8 Bil

Sponsor Center